F10 and cancer: Although the upper bound of the 95% CI of the primary analysis was 1.00, suggesting a possible effect, no difference was found in any of the sensitivity analysis, including an analysis in which we excluded the first year of COVID-19 during which fewer cancer diagnosis were made, possibly resulting in fewer cancer incidences in the factor Xa inhibitor group.